NCT05054751 2024-10-10
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Genor Biopharma Co., Ltd.
Phase 3 Completed
Genor Biopharma Co., Ltd.
Weill Medical College of Cornell University
Peking Union Medical College Hospital